Biology Reference
In-Depth Information
Genton, B., et al., 2008.
Plasmodium vivax
and mixed infections are associated with severe
malaria in children: a prospective cohort study from Papua New Guinea. PLoS Med. 5
(6), e127.
Gogtay, N.J., et al., 1999. Efficacies of 5- and 14-day primaquine regimens in the prevention
of relapses in
Plasmodium vivax
infections. Ann. Trop. Med. Parasitol. 93 (8), 809-812.
Goller, J.L., et al., 2007. Regional differences in the response of
Plasmodium vivax
malaria to
primaquine as anti-relapse therapy. Am. J. Trop. Med. Hyg. 76 (2), 203-207.
Grietens, K.P., et al., 2010. Adherence to 7-day primaquine treatment for the radical cure of
P. vivax
in the Peruvian Amazon. Am. J. Trop. Med. Hyg. 82 (6), 1017-1023.
Guerra, C.A., et al., 2010. The international limits and population at risk of
Plasmodium vivax
transmission in 2009. PLoS Negl. Trop. Dis. 4 (8), e774.
Gunasekera, W.M.K.T.d.A.W., et al., 2011. Usefulness of polymerase chain reaction to sup-
plement field microscopy in a pre-selected population with a high probability of malaria
infections. Am. J. Trop. Med. Hyg. 85 (1), 6-11.
Hamedi, Y., et al., 2004. Therapeutic efficacy of artesunate in
Plasmodium vivax
malaria in
Thailand. Southeast Asian J. Trop. Med. Public Health 35 (3), 570-574.
Hankey, D.D., et al., 1953. Korean vivax malaria. I. Natural history and response to chloro-
quine. Am. J. Trop. Med. Hyg. 2 (6), 958-969.
Haque, R., et al., 2007. Therapeutic efficacy of artemether-lumefantrine for the treatment
of uncomplicated
Plasmodium falciparum
malaria in Bangladesh. Am. J. Trop. Med. Hyg.
76 (1), 39-41.
Harris, I., et al., 2010. A large proportion of asymptomatic
Plasmodium
infections with low
and sub-microscopic parasite densities in the low transmission setting of Temotu Prov-
ince, Solomon Islands: challenges for malaria diagnostics in an elimination setting. Malar.
J. 9 (1), 254.
Hasugian, A.R., et al., 2007. Dihydroartemisinin-piperaquine versus artesunate-amodiaquine:
superior efficacy and posttreatment prophylaxis against multidrug-resistant
Plasmodium
falciparum
and
Plasmodium vivax
malaria. Clin. Infect. Dis. 44, 1067-1074.
Hasugian, A.R., et al., 2009. In vivo and in vitro efficacy of amodiaquine monotherapy for
treatment of infection by chloroquine-resistant
Plasmodium vivax
. Antimicrob. Agents
Chemother. 53 (3), 1094-1099.
Hay, S.I., et al., 2004. The global distribution and population at risk of malaria: past, present
and future. Lancet Infect. Dis. 4, 327-336.
Hill, E., Amatuzio, D.S., 1949. Southwest Pacific vivax malaria: clinical features and observa-
tions concerning duration of clinical activity. Am. J. Trop. Med. s1-29 (2), 203-214.
Huh, A.J., et al., 2011. Parasitemia characteristics of
Plasmodium vivax
malaria patients in the
Republic of Korea. J. Korean Med. Sci. 26 (1), 42-46.
Hung, T., et al., 2004. Population pharmacokinetics of piperaquine in adults and children
with uncomplicated falciparum or vivax malaria. Br. J. Clin. Pharmacol. 57 (3), 253-262.
Hutagalung, R., et al., 2005. A randomized trial of artemether-lumefantrine versus meflo-
quine-artesunate for the treatment of uncomplicated multi-drug resistant
Plasmodium
falciparum
on the western border of Thailand. Malar. J. 4, 46.
Hwang, J., et al., 2011. In vivo efficacy of artemether-lumefantrine against uncomplicated
Plasmodium falciparum
malaria in Central Ethiopia. Malar. J. 10, 209.
Imwong, M., et al., 2003. Novel point mutations in the dihydrofolate reductase gene of
Plasmodium vivax
: evidence for sequential selection by drug pressure. Antimicrob. Agents
Chemother. 47 (5), 1514-1521.
Ishikawa, H., et al., 2003. A mathematical model for the transmission of
Plasmodium vivax
malaria. Parasitol. Int. 52 (1), 81-93.
Jeffery, G.M., 1952. The infection of mosquitoes by
Plasmodium vivax
(Chesson strain) during
the early primary parasitemias. Am. J. Trop. Med. Hyg. 1 (4), 612-617.
